Current NDC auxiliary source row compounder:464

This page is keyed by dataset, FDA.report source record ID, and physical source row number. Empty values are shown rather than omitted.

Complete normalized row#

Record Source: ndc_compounder_zip
Product Ndc Raw: 70713-014
Product Ndc: 70713-014
Product Ndc Digits: 70713014
Product Type Name: HUMAN COMPOUNDED DRUG
Proprietary Name: TESTOSTERONE ANASTROZOLE SA2 200MG 20MG
Proprietary Name Suffix: [empty]
Nonproprietary Name: TESTOSTERONE ANASTROZOLE SA2 200MG 20MG
Dosage Form Name: PELLET, IMPLANTABLE
Route Name: SUBCUTANEOUS
Marketing Category Name: OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
Labeler Name: Wells Pharmacy, Inc
Establishment Name: Wells Pharmacy, Inc
Establishment Fei: [empty]
Substance Name: TESTOSTERONE; ANASTROZOLE
Active Ingredients Info: 200 mg; 20 mg
History Active Ingredients Raw: TESTOSTERONE; ANASTROZOLE
History Active Ingredients Info Raw: 200 mg; 20 mg
History Dosage Raw: PELLET, IMPLANTABLE
Dea Schedule: CIII
Package Ndc Raw: 70713-014-01
Package Ndc: 70713-014-01
Package Ndc Digits: 7071301401
Package Ndc11: 70713001401
Package Description: 1 PELLET, IMPLANTABLE in 1 BLISTER PACK (70713-014-01)
Reporting Period Raw: 2025-1
Reporting Period: 2025-1
Normalization Status: valid
Source Url: https://www.accessdata.fda.gov/cder/compounders_ndc_directory.zip
Source Archive: compounders_ndc_directory.zip
Source File: compounders_ndc_directory.txt
Source Date: 2026-09-18
Source Last Modified: Fri, 18 Sep 2026 15:17:23 GMT
Source Archive Sha256: 222f6800f79cb1a0fa79431b7226bd6b34899999dbf086af51004a96774ada98
Source Member Sha256: f8d9743e5616579a34d614887e86a53913efa0a63d3138d59d2f87cbb4d0cc17
Source Record Id: compounder:464
Source Row Number: 464
Source Row Hash: 73c1b66e66c51c7c96a3eaa42337ab50344b0e27a70bdcd5a116023712de77e4
Import Run Id: 20261015T162751Z
Loaded At: 2026-10-15 16:32:20

Exact raw FDA source fields#

{
    "ROUTENAME": "SUBCUTANEOUS",
    "PRODUCTNDC": "70713-014",
    "DEASCHEDULE": "CIII",
    "LABELERNAME": "Wells Pharmacy, Inc",
    "SUBSTANCENAME": "TESTOSTERONE; ANASTROZOLE",
    "DOSAGEFORMNAME": "PELLET, IMPLANTABLE",
    "NDCPACKAGECODE": "70713-014-01",
    "PRODUCTTYPENAME": "HUMAN COMPOUNDED DRUG",
    "PROPRIETARYNAME": "TESTOSTERONE ANASTROZOLE SA2 200MG 20MG",
    "REPORTINGPERIOD": "2025-1",
    "NONPROPRIETARYNAME": "TESTOSTERONE ANASTROZOLE SA2 200MG 20MG",
    "PACKAGEDESCRIPTION": "1 PELLET, IMPLANTABLE in 1 BLISTER PACK (70713-014-01) ",
    "ACTIVEINGREDIENTSINFO": "200 mg; 20 mg",
    "MARKETINGCATEGORYNAME": "OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)",
    "PROPRIETARYNAMESUFFIX": ""
}

Normalization notes#

[]

Current status projection#

Dataset: compounder
Record Source: ndc_compounder_zip
Source Record Id: compounder:464
Source Row Number: 464
Status Scope: package
Lookup Ndc: 70713-014-01
Lookup Ndc Digits: 7071301401
Product Ndc: 70713-014
Product Ndc Digits: 70713014
Package Ndc: 70713-014-01
Package Ndc Digits: 7071301401
Package Ndc11: 70713001401
Product Id: [empty]
Status Code: COMPOUNDER
Status Label: Outsourcing facility compounded drug report
Reporting Period Raw: 2025-1
Reporting Period: 2025-1
Source Table: fda_ndc_aux_compounder
Source File: compounders_ndc_directory.txt
Source Date: 2026-09-18
Source Row Hash: 73c1b66e66c51c7c96a3eaa42337ab50344b0e27a70bdcd5a116023712de77e4
Import Run Id: 20261015T162751Z
Loaded At: 2026-10-15 16:32:20